The interplay of NIAM with p53 and its established partners (ARF, Mdm2 and Tip60), all of which are frequently disrupted in human cancers [3], [14], [17], [21], [22], suggests NIAM may have tumor suppressive activity. This evidence concerns the gene CDKN2A and cancer.